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ABSTRACT 
Background: There is a growing interest in the potential of mesenchymal stem cells 
(MSC) for implementing regenerative medicine.  
Methods: We assessed the effect of intravenous administration of human bone marrow-
derived MSC on the lifespan of a single Sprague-Dawley female rat. The treatment was 
started when the rat was 6 months old and the cells were administered every two weeks 
afterwards.  
Results: The treatment did not induce any obvious changes in body growth or behavior 
and the rat showed the typical age changes for this strain, except that, unlike intact 
counterparts, the animal did not develop mammary tumors or pituitary gland 
hyperplasia. The more remarkable effect of the treatment was on lifespan which was 44 
months as compared with an average of 36 months for intact laboratory rats.  
Conclusions: We conclude that despite the low N value it is likely that the MSC 
treatment was responsible for the exceptionally long survival of the rat. The potential 
rewards of confirming the present findings warrant further studies involving higher N 
values.     
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INTRODUCTION 
Mesenchymal stromal cells (also known as mesenchymal stem cells; MSC) are regarded 
as multipotent progenitors
1
 with the ability to modulate inflammatory responses
2
 and 
migrate to injury sites
3
. They can likely be derived from  almost all tissues, and should 
express certain cell surface  markers, such as CD105, CD73 and CD90 and be negative 
 for hematopoietic cell surface markers (as reviewed in
4
).  Finally, they must be able to 
differentiate into osteoblasts, chondroblasts and adipoblasts
5
.  
There is a growing interest in the therapeutic potential of MSC; thus, administration of 
MSC in different animal models was found to have restorative effects in liver fibrosis
6
, 
myocardial infarction
7
 and Alzheimer’s disease (AD)8. There is also evidence that with 
age, the pool of MSC becomes progressively smaller and the remaining cells lose 
vitality, a fact that led one of us (EM) to hypothesize that there is an age-related stem 
cell exhaustion syndrome which may be responsible for a number a chronic pathologies, 
including aging itself 
9
. Here, we report that long-term intravenous administration of 
human bone marrow-derived MSC in a single female rat was associated with a 
remarkably long survival, 44 months, as compared with an average lifespan of 36 
months for most albino rats.  
 
MATERIAL AND METHODS 
Animals 
Sprague-Dawley rats are raised in our rat colony at INIBIOLP. They are housed in a 
temperature-controlled room (22 ± 2ºC) on a 14:10 h light/dark cycle. Food and water 
are available ad libitum. In our rat colony, the average 50% survival time for females, 
studied in groups of 50-60 animals, is approximately 32 months, provided mammary 
tumors are systematically removed when detected by palpation. The rat under treatment 
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belonged to a group of 50 virgin females to be used in the future when they were 
between 27-29 months old. The rat was placed alone in a standard stainless steel square 
cage. Typically, our female rats show an almost flat survival curve (100 % alive) until 
age 24-26 months when they begin to die in progressively increasing numbers. All 
experiments with animals were performed in accordance to the Animal Welfare 
Guidelines of NIH (INIBIOLP’s Animal Welfare Assurance No A5647-01). IACUC 
approved on April 3
rd 
  2007 and extended on December, 19
th
, 2011. 
Human bone marrow-derived MSC isolation and preparation 
Ten ml heparinized bone marrow blood was sterilely obtained by needle aspiration from 
the ileac bone of a male (56 years old) cadaver donor, in a routine procurement 
procedure at the Buenos Aires Province Ministry of Health Transplantation Agency, 
CUCAIBA, after cardiac arrest and when all other organs and tissues suitable for 
transplantation had been already collected. In this procurement procedure, the donor 's 
bone marrow blood was collected after fulfilling all requirements  as needed by law, for 
organ, tissue and cell transplantation and research. The bone marrow blood was 
transported and processed under sterile conditions. Briefly, blood was diluted in low 
glucose DMEM (Invitrogen), and mononuclear cells collected after density gradient 
centrifugation and cultured for the isolation of MSC in 75 cm
2
 tissue culture flasks at 
37
o
C in a CO2 incubator (5% CO2) at 95% humidity with 10% of selected fetal bovine 
serum (FBS), Invitrogen). Cells were cultured overnight and the adherent cells allowed 
to attach to the plastic flasks. Nonadherent cells were removed and the culture expanded 
for several days, feeding them every 3 days. MSC appeared soon as typical round 
colonies and a monolayer started to form over 14-17 days in every flask. When the cells 
reached 80% confluence, they were detached from the culture flasks, expanded in a 
second passage, phenotyped as CD105, CD73, CD44 and CD90 positive cells, lacking 
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CD45, CD34, CD14, CD11b, CD79, CD19 and HLA-DR surface molecules expression, 
microbiologically tested and caryotyped to confirm they were normal. The MSC were 
then placed in low glucose DMEM with 20% FBS and 10% DMSO and cryopreserved 
in liquid nitrogen. This preparation was the source of MSC for the whole study. For 
each injection, a cell aliquot was thawed and cultured, with regular examination under a 
phase-contrast inverted microscope. Finally, the MSC were detached, concentrated by 
centrifugation, their concentration properly adjusted and delivered to the rat as 
described below.  
Treatment with MSC 
A suspension of MSC in low glucose DMEM  (5x10
6 
cells in 0.5 ml) was injected with 
a tuberculin syringe fitted to a 25G needle, in one of the tail veins. The treatment was 
started at 6 months of age and the MSC injections were administered every two weeks 
until the end of the study.   
 
RESULTS 
The MSC injections did not cause any observable changes in the rat, either beneficial or 
detrimental. As the animal aged it progressively developed bilateral cataracts which 
became severe after 30 months of age. This pathology was also observed in the majority 
of the intact counterparts. Although there is a high incidence of nonmetastatic mammary 
tumors in our aging females (which are surgically removed shortly after detection in 
order to prolong the animals’ life) none was detected in the treated rat. The body weight 
of the experimental rat showed a slight increase as it aged. It was 291g at 27 months, 
314 g at 36 months and 321 g at 42 months. Taken as a reference, fifteen 27-month 
intact counterparts weighed (X±SEM) 287±4 g. At 30 months of age, a 7-day long  
assessment of vaginal smears revealed that the animal was, as expected, in constant 
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anestrus.  At 42 months of age the treated rat showed a mobility and exploratory activity 
roughly comparable to that of 26-month-old intact counterparts when placed on the 
Barnes maze. At this age the rat showed no paralysis or dragging of the hind legs and 
displayed a normal posture (Fig. 1). The animal died at 44 months of age, during the 
night, without having shown overt signs of disease during the previous days. The 
necropsy revealed no tumors or gross pathology in the major organs. A remarkable 
finding was the preserved size of the pituitary gland which is almost invariably enlarged 
or even tumoral in our old female rats at 27-29 months of age. 
The brain was removed and the remainder of the head was frozen and sent to Dr. Steven 
Clarke, Department of Chemistry and Biochemistry and the Molecular Biology 
Institute, University of California at Los Angeles, for an independent determination of 
age by analysis of racemization and isomerization of teeth and eye lens proteins. The 
results are reported in this issue. 
 
DISCUSSION 
The average lifespan of laboratory rats is 3 years
10
 and up to now, calorie restriction 
remains as the only proven intervention able to substantially extend lifespan in rodents. 
It was first demonstrated by the pioneering studies of McCay et al. (1935)
11
 in rats. The 
authors used severe caloric restriction started after weaning in order to retard growth, 
keeping the body weight of the animals at about half the weight of the ad libitum fed 
counterparts. In the females, the maximum life span increased from 1,189 days (39.6 
mo.) in the fully fed rats to 1,421 days (47.4 mo.) in the females calorie restricted after 
weaning. The mortality was high as reflected by the fact that the avearge lifespan of the 
surviving females was 801 (26.7 mo.) and 775 (25.8 mo.) days for control and calorie 
restricted females, respectively.  Comparable results were recorded in males. In young 
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female Sprague-Dawley rats it was shown that 50% food restriction induces a severe 
panhypopituitarism as well as an arrest in ovulation and estrous cyclicity. Upon 
refeedeing, the rats resumed estrous cycles and remained cycling for longer than their 
full-fed counterparts
12
.   
Unlike calorie restricted rats, the MSC treated rat gained weight at the same rate as the 
untreated counterparts and did not show any signs of disease or behavioral 
abnormalities (severely calorie resticted rats show profound behavioral changes 
including cannibalism). Mammary tumors and pituitary hyperplasia or adenoma are the 
two most frequent pathologies in aging Sprague Dawley female rats
13
. Interestingly, our 
experimental rat did not develop mammary tumors during its extended life; nor was its 
pituitary gland enlarged at the time of death.  
The fact that we used a single experimental animal limits the strength of the conclusions 
that can be drawn. Nevertheless, it should be pointed out that it is highly unlikely, 
although possible, that the rat chosen at random for the treatment was one of the 
extremely rare very long-lived individuals that exist in a colony of Sprague Dawley rats. 
Interestingly, heterochronic parabiosis has been reported to extend the lifespan of the 
older member of the parabiotic pair
14
. The intervention extended the maximum lifespan 
of Buffalo female rats from 1,100-1,150 days (37 mo.) in single intact females to 1,150-
1,200 days (39 mo.) in the older member of the heterochronic parabiotic pair. 
Interestingly, Shen at al. (2011)
 15
 reported that bone marrow-derived MSC from young, 
but not from old, mice implanted in full body X-irradiated old (18-24 mo.) female mice, 
moderately but significantly increased their lifespan and slowed their age-related loss of 
bone density. Furthermore, a recent study in F344 male rats showed that long-term 
intravenous treatment (one injection a month) of the animals with human amniotic 
membrane-derived mesenchymal stem cells (AMMSCs) or adipose tissue-derived 
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mesenchymal stem cells (ADMSCs) extended their maximum life span from 23 months 
(saline-injected controls) to 30 and 34 months, respectively. The treatment, that did not 
elicit a significant immune rejection, also improved the increased the concentration of 
acetylcholine and recovered neurotrophic factors in the brain and muscles, leading to 
restoration of microtubule-associated protein 2, cholinergic and dopaminergic nervous 
systems, microvessels, muscle mass, and antioxidative capacity
16
. Although these rats 
were shorter-lived than average rat strains (typical life span, 36 months), the results are 
fully in line with ours and support the hypothesis that stem cell depletion is relevant to 
the process of systemic aging.   
Another study suggests that the plasma from young mice contains molecules able to 
improve cognitive functions in old mice
17
.  Taken together, the above studies are 
consistent with the hypothesis of a stem cell exhaustion syndrome as a relevant 
(although not exclusive) cause of aging and chronic pathologies
9
. The heterologous 
MSC used in the present study came from a patient approaching old age, yet the treated 
rat had a lifespan 22% longer than the avearge lifespan of laboratory rats. Since this is, 
to our knowledge, the first report of a life extending activity of MSC in rats, it would be 
premature to postulate a mechanism for this effect. Clearly, the tolerance of the rat to 
these heterologous MSC was very high. Importantly, preliminary experiments in which 
we intracerebroventricularly administered human MSC to 27-month old female rats or 
streptozotocin-lesioned young males (an AD model) revealed only a mild restorative 
effect on spatial memory. This suggests that MSC therapy must be started during 
adulthood or youth in order to significantly extend life and delay the onset of age-
related pathologies.    
 
Concluding remarks 
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This is a 4.5-year long experiment with a design weakness that stems from the minimal 
N value used, a limitation that is at least partly counterbalanced by the high 
unlikelihood of finding by chance such a long-lived individual in our rat colony. 
Clearly, the results are not conclusive but they invite further exploration. We believe 
that the potential rewards of confirming the present findings warrant investing the time 
and resources needed to replicate the study with a higher N value.     
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FIGURE LEGEND 
Figure 1- Panel A shows from left to right, the treated rat at 42 months of age, an old 
rat at 26 months and a 3 months old young rat. Panel B shows from left to right, the 
treated rat at 43 months, a 28 months old rat and a 4 months old young rat. All animals 
are females. The young and old rats are different animals in A and B. Notice the severe 
cataracts in the treated rat. They are bilateral. One of the old rats also shows cataracts.  
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